Abstract: Acid resistant Oligomers suitable for oral administration, orally acceptable formulations of such Oligomers and preparation of pharmaceutical formations of such Oligomers are provided.

Abstract: There are prepared compounds of the formulae ##STR1## where R is lower alkyl, chlorine, or bromine and n is an integer from 1 to 5. The compounds of formula (1) can be used to make erythro-9-(2-hydroxy-3-nonyl) hypoxanthine and its homologues and also to make the compounds of formulae (2) and (3). All three classes of compounds are useful as immunomodulators.

Abstract: There are prepared compounds of the formulae ##STR1## Where R.sup.1 is H, lower alkyl S--, ##STR2## NH.sub.2 or halogen, R.sup.2 is OH, lower alkyl S--, halogen, NH.sub.2 or SH,R is OH, SH, lower alkyl S--, or halogen andR.sup.3 is OH, SH, lower alkyl S--, halogen or NH.sub.2.The compounds have antiviral and immuno-modulating activity.

Abstract: There are prepared compounds of the formula ##STR1## where R.sup.1 is alkyl of 1 to 8 carbon atoms and R.sup.2 is the ester group of an unsubstituted monocarboxylic acid, aromatic carboxylic acid, aminocarboxylic acid, unsubstituted dicarboxylic acid, phosphoric acid, or nitric acid or a glycoside or an acetaldehyde acetal. The compounds are immunomodulators, have antiviral activity and antitumor activity and also are enzyme inhibitors. The compounds can also be used to introduce the corresponding alcohol into biological systems, in some cases with enhanced potency.

Abstract: There are prepared compounds of the formulae ##STR1## where R is lower alkyl, chlorine, or bromine and n is an integer from 1 to 5. The compounds of formula (1) can be used to make erythro-9-(2-hydroxy-3-nonyl) hypoxanthine and its homologues and also to make the compounds of formulae (2) and (3). All three classes of compounds are useful as immunomodulators.

Abstract: A new solid or liquid dosage form containing deglycyrrhizinated licorice (DGL) has been designed. This form is more suitable for administration to humans than the form previously used because:(1) irritating ingredients, previously included, possessing no activity, have been removed,(2) bulky, ineffective quantities of antacids have been removed, thereby allowing the amount of the active ingredient DGL to be increased per unit, reducing the number of units needed to be consumed (e.g. from 8 to 4 per day),(3) dangerous, neurotoxic ingredients have been removed, and(4) the bitter DGL has been formulated into an acceptable pharmaceutical dosage form that does not need to be chewed because, unlike other formulations, this formulation is formulated in a novel way that allows for complete and rapid disintegration, releasing the active ingredient in a fashion superior to chewing.

Abstract: There are prepared compound of the formulae ##STR1## Where R.sup.1 is H, lower alkyl S--, lower alkyl ##STR2## NH.sub.2 or halogen, R.sup.2 is OH, lower alkyl S--, halogen, NH.sub.2 or SHR is OH, SH, lower alkyl S--, or halogen andR.sup.3 is OH, SH, lower alkyl S--, halogen or NH.sub.2.The compounds have antiviral and immunomodulating activity.

Abstract: There are prepared compounds of the formula ##STR1## where R.sup.1 is alkyl of 1 to 8 carbon atoms and R.sup.2 is the ester group of an unsubstituted monocarboxylic acid, aromatic carboxylic acid, aminocarboxylic acid, unsubstituted dicarboxylic acid, phosphoric acid, or nitric acid or a glycoside or an acetaldehyde acetal. The compounds are immunomodulators, have antiviral activity and antitumor activity and also are enzyme inhibitors. The compounds can also be used to introduce the corresponding alcohol into biological systems, in some cases with enhanced potency.

Abstract: Compounds of the formula ##STR1## where X is OH, NH.sub.2, SH, OR or SR (where R is alkyl of 1 to 4 carbon atoms or benzyl), R.sup.1 is H or alkyl of 1 to 8 carbon atoms, R.sup.2 is H or methyl, Y is the salt of an amine of the formula ##STR2## where R.sup.3 and R.sup.4 are lower alkyl, e.g., 1 to 4 carbon atoms and n is an integer of 2 to 4 with p-acetamidobenzoic acid and where z is a number from 0 to 10are useful as immunomodulators, as antiviral agents and in specific cases have anti-leukemic activity. The compounds and compositions where z is 1 to 10 are novel per se. When R.sup.2 is H the presence of Y enhances the immunoregulatory activity and the antiviral activity. If X is the NH.sub.2 there is immunoinhibitory activity but no immunostimulatory (immunopotentiatory) activity.

Abstract: Compounds of the formula ##STR1## where X is OH, NH.sub.2, SH, OR or SR (where R is alkyl of 1 to 4 carbon atoms or benzyl), R.sup.1 is H or alkyl of 1 to 8 carbon atoms, R.sup.2 is H or methyl, Y is the salt of an amine of the formula ##STR2## where R.sup.3 and R.sup.4 are lower alkyl, e.g., 1 to 4 carbon atoms and n is an integer of 2 to 4 with p-acetamidobenzoic acid and where z is a number from 0 to 10 are useful as immunomodulators, as antiviral agents and in specific cases have anti-leukemic activity. The compounds and compositions where z is 1 to 10 are novel per se. When R.sup.2 is H the presence of Y enhances the immunoregulatory activity and the antiviral activity. If X is the NH.sub.2 there is immunoinhibitory activity but no immunostimulatory (immunopotentiatory) activity.

Abstract: Compounds of the following structure are disclosed which are effective inhibitors of the enzyme xanthine oxidase: ##STR1## R is an aromatic or substituted aromatic nucleus such as phenyl, R.sub.1 is H, an alkali metal or ammonium, and R.sub.2 is H or OR.sub.1.